Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Adrenal Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1603701

This article is part of the Research TopicNew Insights in the Management of Congenital Adrenal HyperplasiaView all 4 articles

Optimizing Glucocorticoid Therapy in Congenital Adrenal Hyperplasia and Analog Conditions: The Intersection of Dose Reduction, Patient Care, and Coverage in the US

Provisionally accepted
Ahmed KhattabAhmed Khattab1Hyunwoo KimHyunwoo Kim2*Mary MulrooneyMary Mulrooney3Brian LeinwandBrian Leinwand3Nandini HadkerNandini Hadker3Samantha CiceroSamantha Cicero2Henry ChengHenry Cheng2
  • 1Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
  • 2Neurocrine Biosciences Inc, San Diego, United States
  • 3Trinity Life Sciences, Waltham, MA, United States

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Steroids are common treatments used in many diseases for different benefits such as to decrease inflammation or to replace hormones when a person's body may not make enough. However, their use may cause side effects that can last a long time. The way insurance companies think about medications that reduce steroid dose, and how their decisions impact whether to cover a medication that reduces steroid dose, is not well understood. This study shows that insurance companies are concerned about side effects of steroids. Medications that reduced steroid dose were covered along with steroids or offered in place of steroids.

Keywords: glucocorticoid-reducing therapies, payer, congenital adrenal hyperplasia, Survey, corticosteroids, glucocorticoid dose reduction

Received: 31 Mar 2025; Accepted: 18 Aug 2025.

Copyright: © 2025 Khattab, Kim, Mulrooney, Leinwand, Hadker, Cicero and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hyunwoo Kim, Neurocrine Biosciences Inc, San Diego, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material